Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study

Trial Profile

Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Atherosclerosis; Myocardial infarction; Myocardial reperfusion injury
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms REPERATOR
  • Most Recent Events

    • 31 Aug 2009 Results were presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
    • 08 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top